MarketPulse
R

$REGN

15 articles found
9 positive
0 negative
6 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi and Regeneron's Dupixent Wins Japan Approval for Rare Skin Disorder

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.
SNYREGNmonoclonal antibodyclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Dupixent Wins Japan Approval for Rare Autoimmune Disorder, Expanding Sanofi-Regeneron Pipeline

Sanofi and Regeneron's Dupixent secured Japanese regulatory approval for bullous pemphigoid, marking the drug's seventh indication in Japan with superior remission rates versus placebo.
SNYREGNclinical trialDupixent
GlobeNewswire Inc.GlobeNewswire Inc.··Cytomx Therapeutics, Inc.

CytomX Raises $250M via Stock Offering to Fund Varseta-M Development

CytomX Therapeutics prices $250M stock offering at $5.30/share to fund Varseta-M development and pipeline advancement, closing March 2026.
AMGNBMYCELGrREGNMRNA+1colorectal cancerpublic offering
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Weight-Loss Dominance Faces Pipeline Challengers, But Lead Remains Secure

Eli Lilly dominates weight-loss pharmaceuticals with 45% 2025 revenue growth, maintaining market lead despite competitor advances due to years-long regulatory timelines.
LLYNVORHHBYREGNclinical trialsweight loss drugs
GlobeNewswire Inc.GlobeNewswire Inc.··Regeneron Pharmaceuticals, Inc. And Society For Science

Regeneron Extends $150M Science Talent Search Commitment Through 2036

Regeneron commits $150M through 2036 to Science Talent Search, awarding $1.8M to 40 finalists in STEM fields.
REGNcancer treatmentScience Talent Search
GlobeNewswire Inc.GlobeNewswire Inc.··Regeneron Pharmaceuticals, Inc. And Society For Science

Regeneron Commits $150M More to Science Talent Search Through 2036

Regeneron awards $1.8M to 40 high school finalists in 2026 Science Talent Search; extends sponsorship with $150M commitment through 2036.
REGNScience Talent SearchSTEM education
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Lamzede Market Poised for Expansion as Rare Disease Treatments Gain Momentum

Lamzede market expands globally, led by Europe with fastest growth in Asia-Pacific, driven by rare disease diagnostic advances and enzyme replacement therapy adoption.
REGNpersonalized medicinebiotechnology
The Motley FoolThe Motley Fool··Adria Cimino

Two Biotech Leaders Poised for Growth in 2026: REGN and VERX

Regeneron and Vertex Pharmaceuticals emerge as compelling 2026 biotech investments, with REGN valued at 17x and VERX at 24x forward earnings, offering growth and stability respectively.
VRTXREGNpharmaceutical growthinvestment recommendation
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Skeletal Dysplasia Market Set to Surge 54% to $5.37B by 2032

Global skeletal dysplasia market projected to grow from $3.48B (2026) to $5.37B (2032) at 7.42% CAGR, driven by diagnostic advances and innovative therapies.
PFENVSRAREREGNBMRNrare diseasebiologic therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Visiongain

Ophthalmic Drug Market to Reach $41.88B by 2026 Amid Innovation Wave

Global ophthalmic drug market projected to reach $41.88B by 2026, growing 7.9% annually driven by biologic therapies, advanced delivery systems, and AI-enabled diagnostics.
PFEABBVNVSALCRHHBY+3AMDbiologics
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Regeneron's Pipeline Depth and Dupixent Dominance Set Stage for Decade of Growth

Regeneron's Dupixent dominance and deep pipeline across weight management, oncology, and rare diseases position the company for sustained growth through the mid-2030s.
REGNbiotechpatent cliff
BenzingaBenzinga··Vandana Singh

FDA Expands Dupixent Approval to Allergic Fungal Rhinosinusitis

FDA approves Dupixent for allergic fungal rhinosinusitis in patients six and older, marking the drug's ninth indication for treating type 2 inflammatory conditions.
SNYREGNFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

CRISPR Therapeutics Posts Strong Gene Therapy Gains as Casgevy Adoption Accelerates

CRISPR Therapeutics reports strong Q4 results with Casgevy gene therapy generating $116M revenue and 147 patient initiations, signaling accelerating adoption and market confidence.
LLYVRTXREGNCRSPARWRsickle cell diseaseCasgevy
GlobeNewswire Inc.GlobeNewswire Inc.··Towards Healthcare

SNP Genotyping Market Poised to Double to $19.5B by 2034

SNP genotyping market projected to grow from $8.08B (2026) to $19.48B (2034) at 11.7% annual rate, driven by personalized medicine adoption and genomic technology advances.
ILMNRHHBYTMOREGNMYGNpersonalized medicineprecision medicine
BenzingaBenzinga··Vandana Singh

Sanofi Shares Slide as Hudson Steps Down; Garijo to Lead Post-AGM

Sanofi CEO Paul Hudson steps down February 17; Belén Garijo takes over post-AGM. Stock fell 4.5% on leadership transition announcement amid vaccine sales decline concerns.
SNYREGNstock declineCEO transition